|
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00731900 |
Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful in patients refractory to other drugs. However its use is restricted by the high incidence of cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working memory and language deficits, at a much higher rate than other antiepileptic drugs. There do not appear to be obvious differences between patients that do or do not experience cognitive ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a genetic contributor.
Condition |
Cognitive Dysfunction |
Drug Information available for: | Topiramate |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Ages Eligible for Study: | 17 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
patients with epilepsy or patients with migraine treated by topiramate
Inclusion Criteria:
Exclusion Criteria:
Contact: Horng-Huei Liou, MD;PhD | 886-2-23123456 ext 8325 | hhl@ntu.edu.tw |
Taiwan | |||||
National Taiwan University Hospital | Recruiting | ||||
Taipei, Taiwan, 100 | |||||
Contact: Horng-Huei Liou, MD;PhD 886-2-23123456 ext 8325 hhl@ntu.edu.tw |
National Taiwan University Hospital |
Principal Investigator: | Horng-Huei Liou, MD;PhD | National Taiwan University Hospital |
Responsible Party: | National Taiwan University Hospital ( Hrong-Huei Liou, MD;PhD ) |
Study ID Numbers: | 9561707009 |
First Received: | August 7, 2008 |
Last Updated: | August 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00731900 |
Health Authority: | Taiwan: Department of Health |
|
|